PHOSLYRA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8592480 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(3 years from now) | |
| US9089528 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Jul, 2027
(3 years from now) | |
| US8591938 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Feb, 2030
(5 years from now) | |
Phoslyra is owned by Fresenius Medcl.
Phoslyra contains Calcium Acetate.
Phoslyra has a total of 3 drug patents out of which 0 drug patents have expired.
Phoslyra was authorised for market use on 18 April, 2011.
Phoslyra is available in solution;oral dosage forms.
Phoslyra can be used as use of phoslyra for reduction of serum phosphorous in patients.
The generics of Phoslyra are possible to be released after 23 February, 2030.
Drugs and Companies using CALCIUM ACETATE ingredient
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION;ORAL
How can I launch a generic of PHOSLYRA before it's drug patent expiration?
More Information on Dosage
PHOSLYRA family patents
